1434639-57-2

Basic information

• Product Name: ND-646
• Synonyms: ND-646
• CAS NO: 1434639-57-2
• Molecular Formula: C₂₈H₃₂N₄O₇S
• Molecular Weight: 568.64128
• EINECS: -0
• Mol File: 1434639-57-2.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ND-646(CAS DataBase Reference)
• NIST Chemistry Reference: ND-646(1434639-57-2)
• EPA Substance Registry System: ND-646(1434639-57-2)

Safety Data

• Hazardous Substances Data: 1434639-57-2(Hazardous Substances Data)

Usage

General Description

ND-646 is a novel and potent acetyl-CoA carboxylase (ACC) inhibitor that is being developed as a potential therapy for various metabolic disorders, including non-alcoholic steatohepatitis (NASH), type 2 diabetes, and dyslipidemia. ND-646 has shown promising results in preclinical studies, demonstrating significant reductions in liver fat accumulation, improved insulin sensitivity, and lowered levels of circulating triglycerides and cholesterol. ND-646 works by inhibiting the activity of ACC, an enzyme involved in fatty acid biosynthesis, leading to decreased production of lipids in the liver and improved overall metabolic health. Clinical trials are currently underway to further assess the efficacy and safety of ND-646 in the treatment of metabolic diseases.

Upstream product

• 1434635-54-7 1,4-dihydro-1-[(2R)-2-(2-methoxyphenyl)-2-[(tetrahydro-2H-pyran-4-yl)oxy]ethyl]-α,α,5-trimethyl- 6-(2-oxazolyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-3(2H)-acetic acid 

Relevant articles and documents

Synthesis and anti-cancer activity of ND-646 and its derivatives as acetyl-CoA carboxylase 1 inhibitors

Acetyl-coA carboxylase 1 (ACC1) is the first and rate-limiting enzyme in the de novo fatty acid synthesis (FASyn) pathway. In this study, through public database analysis and clinic sample test, we for the first time verified that ACC1 mRNA is overexpressed in non-small-cell lung cancer (NSCLC), which is accompanied by reduced DNA methylation at CpG island S shore of ACC1. Our study further demonstrated that higher ACC1 levels are associated with poor prognosis in NSCLC patients. Besides, we developed a novel synthetic route for preparation of a known ACC inhibitor ND-646, synthesized a series of its derivatives and evaluated their activity against the enzyme ACC1 and the A549 cell. As results, most of the tested compounds showed potent ACC1 inhibitory activity with IC50 values 3–10 nM. Among them, compounds A2, A7 and A9 displayed strong cancer inhibitory activity with IC50 values 9–17 nM by impairing cell growth and inducing cell death. Preliminary SAR analysis clearly suggested that (R)-configuration and amide group were vital to ACC1 and A549 inhibition, since compound (S)-A1 (the enantiomer of ND-646) had poor activity of ACC1 inhibition and the carboxylic acid ND-630 almost lost anticancer effect on A549 cells. Collectively, these findings indicate that ACC1 is a potential biomarker and target for non-small-cell lung cancer, and ND-646 and its derivatives as ACC1 inhibitors deserve further study for treatment of NSCLC.